Skip to main content
. 2010 Jun 30;31(18):2246–2252. doi: 10.1093/eurheartj/ehq203

Table 3.

Indication for implantable cardioverter–defibrillator implantation and underlying heart disease in the 40 recipients of Sprint Fidelis leads

Study group (n = 40)
Indications for ICD implantation
 Primary prevention 26 (65%)
 Secondary prevention 14 (35%)

Underlying heart disease
 Ischaemic heart disease 32 (80%)
 Dilated non-ischaemic cardiomyopathy 3 (7.5%)
 Genetic disorders 2 (5%)
 Others 3 (7.5%)

Values are number and (%) of patients.